Close Menu

NEW YORK (GenomeWeb News) – Cancer Genetics today increased the proposed amount it is seeking to raise from a public offering of its common stock.

In an amended Form S-1, the Rutherford, NJ-based cancer diagnostics firm said that it plans to offer $50 million of its common shares. When the company announced the offering earlier this month, it said that the proposed maximum aggregate offering price would be $46 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Hastings Center's Erik Parens argues in a Scientific American opinion piece that the current pandemic underscores the need to reconsider the hope placed in genomic medicine. 

The Los Angeles Times writes that Operation Warp Speed has an ambitious timeline for developing a COVID-19 vaccine.

The Sydney Morning Herald reports that Australia is launching its trial of preconception carrier testing Tuesday.

In PNAS this week: autosomal genes commonly affected by loss-of-function variants, variants implicated in testis development disorders, and more.

Jul
15
Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.